Literature DB >> 10786994

Herpes simplex replication and dissemination is not increased by corticosteroid treatment in a rat model of focal Herpes encephalitis.

K A Thompson1, W W Blessing, S L Wesselingh.   

Abstract

Neurological damage in Herpes simplex type 1 encephalitis results from neuronal cell death secondary to viral invasion, and from inflammatory changes and cerebral oedema secondary to the immune response to the virus. Corticosteroids could have an important role in the management of Herpes simplex encephalitis because their anti-inflammatory action reduces cerebral oedema. However their use has been limited by concerns that their immunosuppressive actions could increase viral replication and spread. The present study examined this issue in a rat model in which injection of HSV-1 into the cervical vagus nerve produced a well-defined focal encephalitis, characterised by an orderly progression of the virus through central neural pathways connected with vagal afferent termination sites in the medulla oblongata. After injection of HSV-1, rats were treated twice a day, either with vehicle (saline, 400 microl i.p.), with acyclovir (30 mg/kg i.p.), with dexamethasone (5 mg/kg i.p.), or with both acyclovir and dexamethasone. Animals were sacrificed after 72 h, and viral load in different brain regions was quantified by computer-assisted measurement of the area occupied by immunohistochemical reaction product. Treatment with acyclovir reduced viral load to 17 +/- 5% of the saline value (P < 0.01). After dexamethasone treatment, the viral load (63 +/- 13% of the saline value) was also reduced (P < 0.05). Treatment with both acyclovir and dexamethasone reduced viral load to 26 +/- 8% of the saline value (P < 0.01 compared with saline, and P > 0.05 compared to acyclovir alone). Our results confirm the effectiveness of acyclovir in a new model of HSV-1 infection, and provide evidence that corticosteroids do not inhibit the antiviral action of acyclovir. In addition corticosteroids may decrease the extent of infection in their own right. The acute time course studied in our model parallels the time course of acute Herpes simplex encephalitis in humans. Our data suggests that corticosteroids are not detrimental when combined with acyclovir in the management of this condition.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10786994     DOI: 10.3109/13550280009006379

Source DB:  PubMed          Journal:  J Neurovirol        ISSN: 1355-0284            Impact factor:   2.643


  24 in total

1.  Experimental herpes simplex virus encephalitis: a combination therapy of acyclovir and glucocorticoids reduces long-term magnetic resonance imaging abnormalities.

Authors:  Uta K Meyding-Lamadé; Christoph Oberlinner; Philipp R Rau; Sonja Seyfer; Sabine Heiland; Johann Sellner; Brigitte T Wildemann; Wolfram R Lamadé
Journal:  J Neurovirol       Date:  2003-02       Impact factor: 2.643

2.  The case for immunomodulatory approaches in treating HSV encephalitis.

Authors:  Chandran Ramakrishna; Harry Openshaw; Edouard M Cantin
Journal:  Future Virol       Date:  2013-03-01       Impact factor: 1.831

Review 3.  Acute encephalitis - diagnosis and management.

Authors:  Mark Ellul; Tom Solomon
Journal:  Clin Med (Lond)       Date:  2018-03       Impact factor: 2.659

Review 4.  Glucocorticoids and central nervous system inflammation.

Authors:  Klaus Dinkel; William O Ogle; Robert M Sapolsky
Journal:  J Neurovirol       Date:  2002-12       Impact factor: 2.643

5.  Poor neurological sequelae of herpes simplex virus encephalitis in an infant despite adequate antiviral and adjunct corticosteroid therapy.

Authors:  Ratna B Basak; Varsha Malpani; Khalid Kakish; Susan Vargese; Nageshwar Chauhan; Andreas Boeck
Journal:  Indian J Dermatol       Date:  2011-11       Impact factor: 1.494

Review 6.  Immunomodulatory Strategies in Herpes Simplex Virus Encephalitis.

Authors:  Jocelyne Piret; Guy Boivin
Journal:  Clin Microbiol Rev       Date:  2020-02-12       Impact factor: 26.132

Review 7.  Acute viral infections of the central nervous system in immunocompetent adults: diagnosis and management.

Authors:  Marie Studahl; Lars Lindquist; Britt-Marie Eriksson; Göran Günther; Malin Bengner; Elisabeth Franzen-Röhl; Jan Fohlman; Tomas Bergström; Elisabeth Aurelius
Journal:  Drugs       Date:  2013-02       Impact factor: 9.546

8.  Neurocritical care of patients with central nervous system infections.

Authors:  Andreas H Kramer; Thomas P Bleck
Journal:  Curr Treat Options Neurol       Date:  2008-05       Impact factor: 3.598

9.  Host strain-dependent difference in susceptibility in a rat model of herpes simplex type 1 encephalitis.

Authors:  Biborka Bereczky-Veress; Olle Lidman; Farideh Sabri; Ivan Bednar; Fredrik Granath; Tomas Bergström; Christian Spenger; Alf Grandien; Tomas Olsson; Fredrik Piehl; Margarita Diez; Birgit Sköldenberg
Journal:  J Neurovirol       Date:  2008-04       Impact factor: 2.643

10.  Protocol for German trial of Acyclovir and corticosteroids in Herpes-simplex-virus-encephalitis (GACHE): a multicenter, multinational, randomized, double-blind, placebo-controlled German, Austrian and Dutch trial [ISRCTN45122933].

Authors:  Francisco Martinez-Torres; Sanjay Menon; Maria Pritsch; Norbert Victor; Ekkehart Jenetzky; Katrin Jensen; Eva Schielke; Erich Schmutzhard; Jan de Gans; Chin-Hee Chung; Steffen Luntz; Werner Hacke; Uta Meyding-Lamadé
Journal:  BMC Neurol       Date:  2008-10-29       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.